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Abstract
Background: Menopause is the onset of aging in women. During this process, some women experience physical
changes that may impact upon their psychological and social status, also affecting their quality of life. Furthermore,
several psychological changes following menopause have been shown to act as pro-oxidant, but the association
between the psychological status that modify the quality of life and oxidative stress in postmenopausal women is
still unclear. The aim of this study was to determinate the relationship between oxidative stress with psychological
disturbances, low self-esteem, depressive mood and anxiety, and quality of life in the postmenopausal women.
Methods: We carried out a cross-sectional study with101 premenopausal and 101 postmenopausal women from
Mexico City. As markers of oxidative stress we measured plasma lipoperoxide levels, erythrocyte superoxide
dismutase and glutathione peroxidase activities, and total antioxidant status. We calculate a stress score as
global oxidative stress status, with cut-off values for each parameter; this score range from 0 to 6, representing
the severity of markers modifications. All the women were rated using the Coopersmith Self-Esteem Inventory,
the Zung Self-Rating Anxiety and the Zung Self-Rating Depression Scales, and the WHO Quality of Life-brief.
Results: The postmenopausal women with low quality of life in the WHO Quality of Life-brief and their
subscales had higher stress score compared with premenopausal women with high quality of life (p < 0.05).
We found a positive correlation among lipoperoxide levels and Zung Self-Rating Anxiety and Zung Self-Rating
Depression score (r = 0.226 and r = 0.173, respectively, p < 0.05), and a negative correlation with WHO Quality of
Life-brief scores (r = −0.266, p < 0.01) in postmenopausal women. Multiple linear regression analysis revealed that
average lipoperoxide levels increase by 0.0007 μmol/L for every 1-point increase in the Coopersmith Self-Esteem
Inventory and by 0.001 μmol/L for every 1-point decrease in the WHO Quality of Life-brief, after adjusted for
pro-oxidant factors. Zung Self-Rating Anxiety and Zung Self-Rating Depression Scales scores also contribute to
increase lipoperoxides levels, but not significant.
Conclusion: Our findings suggest that oxidative stress is increased in postmenopausal women with psychological
disturbances and low quality of life.
Keywords: Oxidative stress, Psychological disturbances, Quality of life, Menopause
* Correspondence: masanrod@yahoo.com.mx
1Unidad de Investigación en Gerontología, Facultad de Estudios Superiores
Zaragoza, Universidad Nacional Autónoma de México, Av. Guelatao No. 66,
Iztapalapa, CP 09230 México, D.F., México
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sánchez-Rodríguez et al. BMC Women's Health  (2017) 17:1 
DOI 10.1186/s12905-016-0358-7
Background
In women, postmenopause is a critical period due to a
series of endocrinological changes that are caused by
the decline of production of estrogens by the ovaries
(mainly estradiol) that lead to low estrogen levels.
Although menopause is a natural process, some women
experience physiological changes that may interfere
with their ability to cope with their new psychological
and social status and affect their quality of life [1, 2].
In this context, estrogen depletion affects many tissues
of the body, including brain cells. Furthermore, the pres-
ence of steroid hormone receptors in various brain regions
has been demonstrated, and it is known that estrogens
increase cerebral blood flow, which prevents neuronal
atrophy and enhances sleep, memory, cognition and other
neurologic functions that are affected with low level of
estrogens once menopause happens [3, 4]. The age-
associated malfunction of human cells results from the
physiological accumulation of irreparable damage to bio-
molecules, which is an unavoidable side effect of normal
aerobic metabolism in a process termed as oxidative
stress (OS).
Oxidative stress occurs when the antioxidant system is
unable to effectively deal with the reactive oxygen species
(ROS) and free radicals produced in living organisms.
These ROS and free radicals then cause oxidative damage
to biomolecules such as lipids, proteins and DNA, which
leads to dysregulation of normal metabolism and physi-
ology [5, 6]. Under normal conditions, ROS are cleared by
antioxidants such as the enzymes superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx), or
by non-protein molecules [7], such as estrogens. These
antioxidants are able to either prevent the generation of
oxidizing species or reduced the oxidative effects of the
ROS. As well as sex hormone, estrogens have free radical
scavenging capacity present in the phenolic ring in A pos-
ition and thus can function as antioxidant to inhibit the
generation of ROS or neutralize excess ROS [8]. The evi-
dence for the antioxidant activity of estrogens came from
neurological, cardiovascular and metabolic fields [8, 9];
moreover, we previously suggested that depletion of estro-
gen in postmenopausal women could also cause OS [10].
Furthermore, most of the symptoms after menopause,
such as insomnia, depressive mood and anxiety, are con-
sidered pro-oxidants [11–13] affecting the health and so-
cial status of menopausal women and therefore their
quality of life. As we indicated previously, estrogens might
have neuroprotective properties, such as controlling neur-
onal activity related to the process of cognition and the
modulation of mood and other mental states, and improv-
ing learning and memory [9]; however, the association
between the psychological status that modify the quality
of life and oxidative stress in postmenopausal women is
still unclear. Therefore, the aim of this study was to
determinate the relationship between OS with psycho-
logical disturbances and quality of life in the postmeno-
pausal period.
Methods
Study design and population
A community-based cross-sectional study was conducted
in perimenopausal women from Mexico City, Mexico.
They were invited to participate in the project
“Menopause and oxidative stress” directed by the
Gerontology Research Unit at Universidad Nacional
Autonoma de Mexico, Zaragoza Campus, from Novem-
ber 2013 to May 2014. The baseline sample consists of
240 women recruited by advertisements placed near the
university campus. The women were selected to estab-
lish two groups, premenopausal and postmenopausal.
The main eligibility criteria for premenopausal women
were that they had to be 40 to 52 years old; besides,
they most still have menstrual period and they most ex-
perience menopausal symptoms, e.g. depressive mood,
hot flashes, and sleep disturbances. For postmenopausal
women, they had to be 48 to 59 years old and have at
least 12 months of spontaneous amenorrhea and/or
serum estradiol levels below 25 pg/mL and FSH levels
higher than 50 mU/mL, both groups were free of car-
diovascular and cancer diseases, without antioxidant
supplement intake for at least six months prior to the
beginning of the study, and without hormone therapy
intake. Twenty-five women had no further interest in
the study and seven were excluded because their age
was more than 60 years old.
The selected women underwent the following examina-
tions: complete clinical history, biochemical analysis,
complete blood count, anthropometric and blood pressure
measurements, after a 12-h fasting period. Those tests
were used to establish their health status, and cut-off
points for reference values for Mexican adults were deter-
mined at the Gerontologic Clinical Research Laboratory of
the Universidad Nacional Autónoma de México, Zaragoza
Campus in Mexico City [14]. The intra- and inter- assay
variation coefficients of hematological and biochemical
tests were less than 5% in all determinations. Also, we
measured estrogens and FSH levels. The within-run preci-
sion levels for these methods were 3.1 and 7.4%, respect-
ively, and the estrogens analytical sensitivity was 8 pg/mL.
Sample size
The sample size was calculated based on a two proportion
principle on the assumptions of a proportion of postmen-
opausal women (83%) and other of premenopausal
women (56%), both with high lipoperoxides levels (LPO)
and acute symptoms, as we previously reported [10]; using
a 5% level of significance with a power of 90%. To detect a
difference of 27% in the proportions, we estimated sample
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size approximated by the chi square test with Yates’s con-
tinuity correction. To compute the sample size, we used
the tables for clinical studies [15]. We added 20% of the
calculated sample size to compensate the expected non-
response. The final size obtained was 190 women, but to
ensure the results, we selected 101 randomized women by
group.
Oxidative stress measurement
We measured red blood cell superoxide dismutase (SOD)
activity by the method of xanthine oxidase; red blood cell
glutathione peroxidase (GPx) activity by the oxidation of
glutathione; and plasma total antioxidant status (TAS) by
2,2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, ABTS
+) radical formation kinetics, all the assays with commer-
cial kits (Randox Laboratories, Ltd., Crumlin Co. UK).
Also we measured plasma lipoperoxides levels (LPO) with
thiobarbituric acid reacting substances (TBARS) assay
described by Jentzsch et al. [16]. All the methods were
validated in our research laboratory and the within-run
precision for the markers were as follows: 3.8, 4.6, 4.3, and
6%, respectively [10]. Artefactual formation of TBARS in
the samples was prevented by adding 10 μL of 2-mM
butylated hydroxytoluene (BHT) in ethanol at 95% imme-
diately after centrifugation. The measures were performed
in a Shimadzu UV-1601 UV–vis spectrophotometer
(Kyoto, Japan).
In addition, we calculated SOD/GPx ratio, and antioxi-
dant gap with the equation [17]:
GAP ¼ TAS – albumin μmolð Þ X 0:69ð Þ þ uric acid μmolð Þ½ ð
Alternative cut-off values of each parameter were de-
fined on the basis of the 90th percentile of young healthy
subjects: LPO ≥0.320 μmol/L, SOD ≤1.20 U/gHb, GPx
≤50.1 U/gHb, TAS ≤900 μmol/L, SOD/GPx ≥0.023, GAP
≤190 μmol/L. A stress score (SS) ranging from 0 (no
oxidative stress) to 6 (severe oxidative stress) was calcu-
lated as oxidative stress status; a score 1 was given to each
value higher or lower than the cut-off.
Assessment of psychological status and pro-oxidant factors
The women were rated using validated self-assessment
questionnaires in the Spanish version, and a structured
questionnaire about pro-oxidant factors. Two trained
bachelor nurses were used as data collectors and a nurse
with a master’s degree was assigned as supervisor, all the
psychology tests were conducted and evaluated by a
psychologist with a master’s degree, coauthor of this
paper.
Self-esteem was evaluated with the Coopersmith Self-
Esteem Inventory (SEI). The minimum score possible is
0 and the maximum score is 100 points. A cut-off value
lower than 50 points was considered to indicate low
self-esteem [18]. The Zung Self-Rating Anxiety Scale
(SAS) was used to assess anxiety, the total score on the
SAS ranges from 0 to 80. A cut-off value higher than 45
points was considered to indicate anxiety [19, 20].
Dysthymia was determined with the Zung Self-Rating
Depression Scale (SDS), the score ranges from 20 to 80.
A woman with a SDS score above 40 points was consid-
ered with dysthymia [21, 22]; and the World Health
Organization Quality of Life, brief (WHOQoL-brief )
served to evaluated the quality of life. This instrument
includes four subscales (physical, psychological, social
relationships and environment) and two global ques-
tions regarding quality of life and overall health [23]. A
cut-off value less than 96 points in the total score,
lower than 26 points in the physical subscale, lower
than 23 points in the psychological subscale, lower than
12 points in the social relationships subscale and lower
than 30 points in the environment subscale were consid-
ered to indicate low quality of life [24]. Finally, the partici-
pants answered a structured questionnaire about pro-
oxidant factors as potential confounders. We considered a
pro-oxidant factor present, for each, when the following
were noted, smoking ≥ 2 cigarettes/day, consumption of ≥
2 glasses/day alcoholic beverages, consumption of > 2
cups/day caffeinated beverages, < 30 min/day of physical
activity, and sleep < 6 h/day.
Data analysis
Data were expressed as the mean ± standard deviation of
the health status variables, tests scores, and oxidative
stress markers in pre- and post-menopausal women; these
values were compared using Student’s t-test. Percentage
differences were evaluated using the chi square test (χ2)
and 95% confidence intervals.
Women were divided into four subgroups based on
menopausal status and psychological disturbances to
find the difference in stress score, as oxidative stress
marker, 1) premenopausal women without psycho-
logical disturbances or with a high quality of life, 2)
premenopausal women with psychological disturbances
or a low quality of life, 3) postmenopausal women with-
out psychological disturbances or with a high quality of
life, and 4) postmenopausal women with psychological
disturbances or a low quality of life. We considered a
woman with psychological disturbances if she has dys-
thymia, anxiety or low self-esteem according to the re-
spective cut-off value in the tests. The differences among
the subgroups were analyzed by one-way ANOVA with
the Dunnett test as post-hoc, using subgroup 1 as control
group.
Pearson correlation analyses were calculated to study
the association between the tests scores and oxidative
stress, using LPO levels as oxidative stress marker,
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obtaining the relationship between each of the two
groups, pre-and postmenopausal women. We selected
LPO levels because they showed the biggest difference
among all the oxidative stress markers according to de-
scriptive analysis. Multiple linear regression analyses
were performed to examine the association between
LPO as dependent variable and the test scores as inde-
pendent variables in both pre- and postmenopausal
women. All the models were adjusted for number of
cigarettes consumed and hours of sleep by day and
BMI, as life-style pro-oxidant factors. Other life-style
pro-oxidant factors were not included because they
were very frequent (caffeinated beverages intake) or in-
frequent (alcohol intake and physical activity).
The level of statistical significance was set at a two-
tailed p-value of 0.05. The data were processed by use of
the standard statistical software package SPSS V. 20.0
(IBM SPSS Statistics Armonk, NY, USA).
Results
Sample characteristics
The biochemical-hematologic parameters, anthropomet-
ric and blood pressure measurements, and oxidative
stress markers of the study participants are presented in
Table 1. It was observed that women in both groups had
similar values in all parameters, except in red blood
count (p < 0.05). About of oxidative stress markers, LPO
levels were higher and the activity of antioxidant enzymes
were lower in postmenopausal compared with premeno-
pausal women (p < 0.05).
Psychological status in pre- and postmenopausal women
Postmenopausal women have lower self-esteem, 32 (32%,
95% CI: 23-41%) vs. 12 (12%, 95% CI: 6-18%), p = 0.001;
and lower quality of life: 75 (74%, 95% CI: 66-83%) vs. 59
(60%, 95% CI: 49-68%), p < 0.05, compared with premeno-
pausal women. The prevalence of postmenopausal women
reporting effects on their physical and social quality of life
was 64 (63%, 95%CI: 54-73%) and 67 (66%, 95% CI: 57-
76%), respectively, p < 0.01 (Table 2).
Psychological status, quality of life and oxidative stress
In the stratified groups, stress scores were higher in
postmenopausal women with psychological disturbances
in all the tests, compared with premenopausal women
without disturbances, but only statistically significant in
SEI (Fig. 1).
Likewise, we observed that the stress score was higher
in postmenopausal women with low quality of life in all
WHOQoL-brief subscales, except in environmental sub-
scale, compared with premenopausal women with high
quality of life (Fig. 2).
Furthermore, in the univariate analysis, we found a
positive correlation between LPO levels and all the tests,
except for the self-esteem score, and a negative correl-
ation with the total WHOQoL-brief score in postmeno-
pausal women. In this group, only SEI score and total
WHOQoL-brief remained as independent predictors of
LPO levels in the multivariate model. Thereby, multiple
linear regression analysis revealed that average LPO
levels increase by 0.0007 μmol/L for every 1-point
increase in the SEI test and by 0.001 μmol/L for every
1-point decrease in the WHOQoL-brief, after to be
adjusted for the number of cigarettes consumed, hours of
sleep and BMI. Anxiety and dysthymia scores remain
positively associated with LPO levels, but not statistically
Table 1 Baseline characteristics of women by study group
Parameter Premenopausal
women (n = 101)
Postmenopausal
women (n = 101)
p value
Biochemical -hematologic parameters
Hemoglobin (g/dL) 14.0 ± 1.5 14.6 ± 1.4 0.002
Hematocrit (%) 43 ± 3.9 45 ± 3.9 0.003
Erythrocytes (X1012/L) 4.6 ± 0.5 4.8 ± 0.7 0.034
Total leukocytes
(X109/L)
6431 ± 1573 6071 ± 1192 0.070
Glucose (mmol/L) 5.6 ± 2.5 5.2 ± 1.8 0.773
Urea (mmol/L) 9.6 ± 2.1 10.4 ± 2.5 0.085
Uric acid (μmol/L) 274 ± 77 280 ± 77 0.735
Creatinine (μmol/L) 72 ± 15 72 ± 12 0.848
Cholesterol (mmol/L) 5.6 ± 0.9 5.9 ± 1.1 0.057
Triglycerides (mmol/L) 2.0 ± 1.0 2.1 ± 1.1 0.552
HDL-c (mmol/L) 1.5 ± 0.4 1.6 ± 0.4 0.832
Estrogen (pg/mL) 101.7 ± 71.5 12.3 ± 6.2 <0.0001
FSH (mIU/mL) 10.7 ± 12.2 55.2 ± 26.1 <0.0001
Anthropometric and blood pressure measurement
BMI (kg/m2) 28.34 ± 4.4 28.82 ± 4.2 0.427
Systolic blood pressure
(mm Hg)
123 ± 16 126 ± 15 0.208
Diastolic blood
pressure /mm Hg)




0.334 ± 0.05 0.356 ± 0.05 0.005
Superoxide dismutase
(U/g Hb)
1.23 ± 0.17 1.18 ± 0.13 0.023
Glutathione peroxidase
(U/g Hb)
56.2 ± 16.9 50.3 ± 14.5 0.010
Total antioxidant
status (μmol/L)
1020 ± 166 1052 ± 185 0.215
SOD/GPx ratio 0.023 ± 0.007 0.025 ± 0.007 0.061
Antioxidant gap
(μmol/L)
292 ± 170 305 ± 191 0.616
Quantitative data show means ± standard deviation. HDL-c high density
lipoprotein cholesterol, BMI body mass index. The p value was determined
with Student’s t test
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significant; that may be because these are affected by
the pro-oxidant factors included in the model; even so,
when SAS and SDS increase by 1 point, the LPO levels
increase by 0.0004 and 0.0003 μmol/L, respectively
(Table 3).
Similarly, we observed a negative correlation between
LPO levels and each of the WHOQoL-brief subscales
scores in the same group. In multivariate model, the
subscales score remained negatively associated with LPO
levels, except psychological score, after adjusting for the
same pro-oxidant factors; although only social score was
statistically significant. In this model, when the social
score decreased by 1 point, average LPO levels increase
by 0.010 μmol/L, and when the environmental and
physical scores also decrease by 1 point each, LPO levels
increase by 0.001 and 0.0003 μmol/L, respectively.
(Table 4). There were no correlations between any of the
tests and LPO levels in premenopausal women.
Discussion
Menopause occurs earlier in Latin American women
compared with women in USA and Europe; therefore,
the Latin American women suffer for longer periods
[25, 26], affecting their quality of life for longer. The
psycho-neuro-endocrine relationship in social adapta-
tion of women in menopause is recognized, since
many of the endocrine changes affect self-esteem and
mood states during the menopausal transition [27]. In
addition, it has been described that the climacteric
symptoms are directly related to biologic and sociocul-
tural factors that cause low quality of life in postmen-
opausal women [28–32]. In this study, the proportion
of women with low quality of life was different in total
WHOQoL and their subscales, except in psychological
and environmental scales, between pre- and postmen-
opausal women, such as self-esteem. These results are
Table 2 Prevalence of women with psychological disturbances
and low quality of life, by study group, according the score of
tests conducted
Test Premenopausal
women (n = 101)
Postmenopausal













21 (21%, 13–29%) 27 (27%, 18–35%) 0.341
World Health Organization Quality of Life, brief (WHOQoL-brief)
Total score
(Low < 96)
59 (60%, 49–68%) 75 (74%, 66–83%) 0.039
Physical subscale
(Low < 26)
41 (41%, 31–50%) 64 (63%, 54–73%) 0.005
Psychological
subscale (Low < 23)
56 (56%, 47–66%) 62 (61%, 52–71%) 0.686
Social subscale
(Low < 12)
43 (43%, 33–52%) 67 (66%, 57–76%) 0.005
Environmental
subscale (Low < 30)
73 (74%, 65–82%) 83 (82%, 75–89%) 0.150
Data show frequency, percentage and 95% confidence interval. The p value
was determined with chi square test
Fig. 1 Stress score in the study groups stratified by the different psychological status. The p value was determined with ANOVA and Dunnett test
as post hoc, considering the group of premenopausal women without alterations as control group, *p = 0.01
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not consistent with other publications that found a nega-
tive relationship between psychological aspects and post-
menopause [33, 34]. In fact, mood changes were equally
frequent seen in the study groups using specific tests for
anxiety and depression (SAS and SDS), most likely be-
cause the participants were community-dwelling, contrary
to most studies where the women were recruited from
clinical settings. With reference to self-esteem, recent
studies found that aging process and menopausal status
are not related with self-esteem, although they used differ-
ent tests [35, 36].
During postmenopausal period, OS is increased, as we
previously noted, probably by severe symptoms [10]; thus,
it is likely that estradiol exerts its antioxidant action not
only through its chemical structure but through its influ-
ence on natural cellular antioxidant enzyme activity, via
intracellular signaling cascades and by up-regulation of
the expression of antioxidant genes [37, 38], therefore the
postmenopausal women possess reduced antioxidant cap-
acity that induces high lipoperoxide levels. In this study,
we invited other women and increased the sample size,
and confirmed our previous findings. Moreover, as we
noted above, depressive mood and anxiety are consid-
ered pro-oxidant factors, and cause an increment of OS
[12, 13]; therefore, the aim of this study was to establish
the relationship between the OS with psychological dis-
turbances and quality of life in the postmenopausal
period. In this regard, we sought the relationship
Fig. 2 Stress score in study groups, stratified by quality of life and its subscales. The p value was determined with ANOVA and Dunnett test as
post hoc, considering the group of premenopausal women with high quality of life as control group, *p < 0.05, **p < 0.0001, ***p < 0.01. QoL:
quality of life
Table 3 Univariate and multivariate analysis for the relationship
between lipoperoxides levels and the score of the tests conducted
in postmenopausal women
Univariate Multivariate





−0.030 0.385 0.0007 (0.0003) 0.034
Total WHOQoL −0.298 0.002 −0.001 (0.0005) 0.016
Zung Self-Rating
Anxiety
0.256 0.006 0.0004 (0.0005) 0.501
Zung Self-Rating
Depression
0.213 0.018 0.0003 (0.0006) 0.593
Data show Pearson correlation coefficient and p value, and multiple linear
regression parameters, using LPO levels as dependent variable and the scores
of tests as independent variables, the model was adjusted by number of
cigarettes consumed and hours of sleep by day and BMI as pro-oxidant life-style
factors. R = 0.389, R2 = 0.151, p = 0.036
Table 4 Relationship between lipoperoxides levels and the
score of each subscale of the World Health Organization Quality
of Life (brief), in postmenopausal women, with univariate and
multivariate analysis
Univariate Multivariate
Subscale r p value Unstandardized β
(standard error)
p value
Physical −0.209 0.020 −0.0003 (0.002) 0.842
Psychological −0.212 0.019 0.002 (0.002) 0.409
Social −0.405 <0.0001 −0.010 (0.003) 0.002
Environmental −0.271 0.004 −0.001 (0.002) 0.409
Data show Pearson correlation coefficient and p value, and multiple linear
regression parameters using LPO levels as dependent variable and the
subscale scores of WHOQoL-brief as independent variables; the model was
adjusted by number of cigarettes consumed and hours of sleep by day and BMI
as pro-oxidant life-style factors. R = 0.423, R2 = 0.179, p = 0.012
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between each subscale of WHOQoL and other tests
that evaluated mood changes and self-esteem to estab-
lish whether the intensity of postmenopausal discom-
fort increased OS.
Among the various functions of estrogens, one of the
most important is their role in the functional integrity
of the central nervous system [9, 39]; hence, when go-
nadal function (estrogen production) begins to decline
in women, there is an increase in alterations that cause
OS, such as depressive mood, anxiety and insomnia.
When we stratified by psychological disturbances and
menopausal status, we observed that postmenopausal
women with anxiety or depressive mood had higher
stress score than premenopausal women without mood
changes. Corroborating the evidence that those psycho-
logical disturbances produce OS, we showed a positive
relationship between the scores of the tests used in this
study and lipoperoxide levels in a multivariate model.
In relation to anxiety, Bouayed et al. (2009) [40] pointed
out a link between OS and high-anxiety-related behavior,
confirming our findings; however, the analyzed studies in
the literature review did not explain the underlying
mechanisms. Some studies have indicated an associ-
ation between OS and psychological depressive symp-
toms in females, and shown a potential link between
depression and cancer due to oxidative DNA damage
via neutrophil activation [12, 41–43].
By associating the changes in quality of life and self-
esteem with OS, we found that the postmenopausal
women with low quality of life or self-esteem have high
OS, measurement by stress score, and when we used lipo-
peroxide levels as OS marker, remains only the association
with quality of life during postmenopause, probably be-
cause the change in the levels of this marker is higher than
the other markers after menopause. This relationship is
reflected in the physical, social and environmental sub-
scales of the WHOQoL. In this sense, this test establishes
the improvement of the quality of life [24]; that is why
negative correlations were observed in the multivariate
model. Additionally, psychological alterations in the
WHOQoL questionnaire were associated with OS in uni-
variate analysis, corroborating the findings with tests that
determine anxiety and dysthymia; although in multivariate
analysis this relationship is lost.
With regard to the social and environmental dimensions
of the WHOQoL, we observed a negative correlation be-
tween LPO levels and subscale scores in the postmeno-
pausal women. We were not able to find reports in the
literature that describe associations between dimensions
social and environmental and OS; but some authors sug-
gest that some alterations related to menopause, such as
vasomotor symptoms, causes quality of life changes [27]
and the psychological symptoms are related to the life
events. Life events, family dysfunction and poor social
support are important modulators of menopausal symp-
toms, and the severity of postmenopausal symptoms has
been correlated to how problems are handled, suggesting
that vulnerability to stress contributes to worsening of
menopausal symptoms [44, 45]. Then, the findings of our
study suggest that postmenopausal psychological changes
alter their social and environmental aspects of quality of
life producing an increase of OS.
Also, our results show that the postmenopausal women
with low self-esteem had high stress score compared with
premenopausal women with high self-esteem.
As we noted, during menopause many women experi-
ence negative symptoms that affect their quality of life
and, therefore, their feelings as well as their self-esteem.
Indeed, health status after the menopause is associated
with feelings of body shame and lower psychological
well-being compared with health status during the re-
productive stage [46], these feeling of shame and lower
psychological well-being causes an increase in OS.
Finally, the potential impact of the perception of qual-
ity of life and self-esteem on OS has not previously in-
vestigated; therefore, the importance of this work is that
it shows that psychological changes, low quality of life
and low self-esteem cause an increase in OS. It is im-
portant to consider that it is a cross-sectional study and
therefore the sample may not be representative; then, it
is necessary to carry out prospective studies with repre-
sentative samples to confirm our findings.
Conclusion
Our findings suggest that oxidative stress is increased in
postmenopausal women with dysthymia, anxiety and
low quality of life, may be associated to estrogens deple-
tion; hence it is likely that if women with psychological
alterations are put under hormone therapy with estrogen
or another relief treatment, their quality of life and self-
esteem will improve and, therefore, decrease their OS.
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